top of page
  • X
  • LinkedIn
  • Instagram
Asset 1mail.png
2087579710.jpg

Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences.

Application of omics technologies, and bioinformatics approaches  could identify biological pathways and molecules responsible for the onset, progression and resistance to therapy.

Latest News

Asset 8partner 3.png

Consortium

An interdisciplinary approach bringing together clinicians and researchers aiming to integrate epidemiological, clinical and experimental datasets in order to create a molecular model of cellular processes associated with the onset of active MM and response to therapy. 

Elucidation of risk factors and health determinants associated with Progression of Monoclonal Gammopathies to Multiple Myeloma

In order to achieve the successful complementation of ELMUMY objectives,

the work-plan is wisely organized and split into the following distinct work packages (WPs):

  • X
  • LinkedIn
  • Instagram

Follow Us

Asset 2BW 2.png
eu_funded_en.jpg

Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

© 2023-2025

bottom of page